The cost-effectiveness of empagliflozin in type 2 diabetes in Denmark: Incorporating cardiovascular outcomes

Lars Holger Ehlers, M Lamotte, S Monteiro, P Holmgaard, E C Frary, Niels Ejskjær

Publikation: Konferencebidrag uden forlag/tidsskriftPosterForskningpeer review

Citationsformater